Review article : Opioid analgesics in the management of pain in patients with cancer. A review

Abstract

Keywords

opioids analgesia receptors tolerance addiction pain cancer.

Get full access to this article

View all access options for this article.

References

Hughes J. , Kosterlitz HW Opioid peptides. Introduction. Br Med Bull 1983; 39: 1-3.

Jaffe JH , Martin WR Opioid analgesics and antagonists. In: Gilman AG , Goodman LS , Gilman A , editors. The Pharmacological Basis of Therapeutics , seventh edition. New York : Macmillan, 1985: 494-554.

Twycross RG , Lack SA Symptom control in far advanced cancer: pain relief. London : Pitman, 1983.

Martin WR , Eades CG , Thompson JA , Huppler RE , Gilbert PE The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976; 197: 517-32.

Pasternak GW High and low affinity opioid binding sites: relationship to mu and delta sites. Life Sci 1982; 31: 1303.

Upton N. , Sewell Rde , Spencer Psj. Differentiation of potent μ - and κ -opiate agonists using heat and pressure antinociceptive profiles and combined potency analysis. Eur J Pharmacol 1982; 78: 421-9.

Carson Djl , Carson ED Fatal dextropropoxyphene poisoning in Northern Ireland. Lancet 1977; 894-7.

Anonymous. Dangers of dextropropoxyphene (editorial). Br Med J 1977; i: 668.

Anonymous. Commonest cause of drug-induced death. Lancet 1985; i: 534.

10.

Whittington RM Dextropropoxyphene deaths: coroner's report . Human Toxicol 1984;3:1755-855.

11.

Whittington RM Dextropropoxyphene addiction. Lancet 1979; ii: 743-4.

12.

Wall R. , Linford Smj , Iftikhar Akhtar M. Addiction to Distalgesic (dextropropoxyphene). Br Med J 1980; i: 1213-14.

13.

Critchley J. , Illingworth RN , Pottage A. , Proudfoot AT , Prescott L. Acute poisoning with Distalgesic. Br Med J 1979; i: 342.

14.

Young RJ , Lawson Aah. Distalgesic poisoning - cause for concern. Br Med J 1980; i: 1045-7.

15.

Anonymous. Distalgesic and its equivalents: time for action. Drug Ther Bull 1983; 21: 17-19.

16.

Gumpel JM Acute poisoning with Distalgesic. Br Med J 1979; i: 551.

17.

Pohland A. , Sullivan HR Analgesics: esters of 4-dialkylamino-1, 2-diphenyl-2-butanols. JAm Chem Soc 1953; 75: 4458-61.

18.

Gruber CM , Miller CL , Finneran J. , Chernish SM The effectiveness of d-propoxyphene hydrochloride and codeine phosphate as determined by two methods of clinical testing for relief of chronic pain . J Pharmacol Exp Ther 1956; 118: 280-5.

19.

Nickander RC , Emmerson JL , Hynes MD , Steinberg MI , Sullivan HR Pharmacologic and toxic effects in animals of dextropropoxyphene and its major metabolite norpropoxyphene: a review. Human Toxicol 1984; 3: 13S-36S.

20.

Crome P. , Gain R. , Ghurye R. , Flanagan RJ Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in elderly hospital patients after single and multiple doses of Distalgesic. Preliminary analysis of results. Human Toxicol. 1984 ; 3: 41S-48S.

21.

Inturrissi CE , Colburn WA , Verebey K. , Dayton HE , Woody GE , O'Brien CP. Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene . Clin Pharmacol Ther 1982; 31;157-67.

22.

Beaver WT Analgesic efficacy of dextropropoxyphene and dextropropoxyphene-containing combinations: a review. Human Toxicol 1984 ; 3: 191S-220S.

23.

Beaver WT Mild analgesics: a review of their clinical pharmacology (part II) . Am J Med Sci 1966;251:576-99.

24.

Perrier D. , Gibaldi M. Influence of first-pass effect on the systemic availability of propoxyphene . J Clin Pharmacol 1972; 12: 449-52.

25.

Beaver WT Aspirin and acetaminophen as constituents of analgesic combinations . Arch Intern Med 1981; 141: 293-300

26.

Huskisson EC Simple analgesics for arthritis. Br Med J 1974; iv: 196-200

27.

Owen M. , Hills LJ How safe is dextropropoxyphene? Med J Aust 1980; 1: 617-18.

28.

Anonymous. Filling the gaps between aspirin and morphine. Drug Ther Bull 1984; 22: 45-7.

29.

Standing Advisory Committee for Haematology of the Royal College of Pathologists. Drug interaction with coumarin derivative anticoagulants. Br Med J 1982; 285: 274-5.

30.

Dam M. , Christiansen J. Interaction of propoxyphene with carbamazepine. Lancet 1977; ii: 509.

31.

Ali NA , Marshall RW , Allen EM , Graham DF , Richens A. Comparison of the effects of therapeutic doses of meptazinol and a dextropropoxyphene/paracetamol mixture alone and in combination with ethanol on ventilatory function and saccadic eye movements. Br J Clin Pharmacol 1985; 20: 631-7.

32.

Findlay Jwa , Jones EC , Butz RF , Welch RM Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. Clin Pharmacol Ther 1978; 24: 60-8

33.

Beaver WT , Wallenstein SL , Rogers A. et al. Analgesic studies of codeine and oxycodone in patients with cancer: I. Comparisons of oral with intramuscular codeine and of oral with intramuscular oxycodone. J Pharmacol Exp Ther 1978; 207: 92-100.

34.

Lasagna L. , Beecher KH The analgesic effectiveness of codeine and meperidine (Demerol). J Pharmacol Exp Ther 1954; 112: 306-11.

35.

Seed JC , Wallenstein SL , Houde RW , Belville JW A comparison of the analgesic and respiratory effects of dihydrocodeine and morphine in man. Arch Int Pharmacodyn 1958 ;116:293-339.

36.

Hart ER N-allylnorcodeine and N-allylnormorphine, two antagonists to morphine . J Pharmacol Exp Ther 1941; 72: 19-26.

37.

Lasagna L. , Beecher HK The analgesic effectiveness of nalorphine and nalorphine-morphine combinations in man. J Pharmacol Exp Ther 1954; 122: 356-63.

38.

Archer S. , Albertson NF , Harris LS et al. Narcotic antagonists as analgesics. Science 1962; 137: 541-43.

39.

Beaver WT , Wallenstein SL , Houde RW , Rogers A. A comparison of the analgesic effects of pentazocine and morphine in patients with cancer. Clin Pharmacol Ther 1966; 7: 740-51.

40.

Paddock R. , Beer EG , Bellville JW , et al. Analgesic and side effects of pentazocine and morphine in a large population of postoperative patients. Clin Pharmacol Ther 1969; 10: 355-65.

41.

Beaver WT , Wallenstein SL , Houde RW , Rogers A. A clinical comparison of the effects of oral and intramuscular administration of analgesics: pentazocine and phenazocine. Clin Pharmacol Ther 1968; 9: 582-97.

42.

Kantor TG , Sunshine A. , Laska E. , et al. Oral analgesic studies: pentazocine hydrochloride, codeine, aspirin, and placebo and their influence on response to placebo. Clin Pharmacol Ther 1966; 7: 447-54.

43.

Daniel JR , Wilkins RD , Nicholson PA Two comparisons of the analgesic activity of orally administered pentazocine, dihydrocodeine and placebo. Br J Anaesth 1971 ; 43: 392.

44.

Moertel CG , Ahmann DL , Taylor WF , Schwartau N. A comparative evaluation of marketed analgesic drugs. N Engl J Med 1972; 286: 813-15.

45.

Robbie DS , Samarasinghe J. Comparison of aspirin-codeine and paracetamol-dextropropoxyphene compound tablets with pentazocine in relief of cancer pain. J Int Med Res 1973; 1: 246-52.

46.

Miller RR Clinical effects of pentazocine in hospitalised medical patients. J Clin Pharmacol 1975; 15: 198-285.

47.

Taylor M. , Galloway DB , Petrie JC et al. Psychomimetic effects of pentazocine and dihydrocodeine tartrate . Br Med J 1978; 2: 1198.

48.

Wood Ajj , Moir DC , Campbell C. et al. Medicines evaluation and monitoring group: central nervous system effects of pentazocine. Br Med J 1974; i: 305.

49.

Houde RW Analgesic effectiveness of the narcotic agonist-antagonists. Br J Clin Pharmacol 1979; 7: 297S-308S.

50.

Inciardi JA , Chambers CD Patterns of pentazocine abuse and addiction . N Y St J Med 1971; 71: 1727.

51.

Swanson DW , Weddige RL , Morse RM Hospitalized pentazocine abusers. Mayo Clin Proc 1973; 48: 85-93.

52.

Showalter CV T's and Blues: abuse of pentazocine and tripelennamine . J Am Med Assoc 1980; 244: 1224-5.

53.

Jasinski DR Human pharmacology of narcotic antagonists . Br J Clin Pharmacol 1979;7:287S-90S.

54.

Lewis JR Evaluation of new analgesics. Butorphanol and Nalbuphine. J Am Med Assoc 1980; 243: 1465-67.

55.

Beaver WT , Feise GA A comparison of the analgesic effect of intramuscular nalbuphine and morphine in patients with postoperative pain. J Pharmacol Exp Ther 1978; 204: 487-96.

56.

Beaver WT , Feise GA , Robb D. Analgesic effect of intramuscular and oral nalbuphine in postoperative pain . Clin Pharmacol Ther 1981; 29: 174-80.

57.

Rance MJ Animal and molecular pharmacology of mixed agonist-antagonist analgesic drugs . Br J Clin Pharmacol 1979; 7: 281S-6S.

58.

Wallenstein SL , Kaiko RF , Rogers AG , Houde RW Clinical analgesic assays of buprenorphine and morphine. Clin Pharmacol Ther 1982; 31: 278.

59.

Bullingham Res , McQuay HJ , Dwyer D. , Allen MC , Moore RA Sublingual buprenorphine used postoperatively: clinical observations and preliminary pharmacokinetic analysis. Br J Clin Pharmacol 1981; 12: 117-22.

60.

Heel RC , Brogden RN , Speight TM , Avery GS Buprenorphine: A review of its pharmacological properties and therapeutic efficacy. Drugs 1979; 17: 81-110.

61.

Bevan PLT, Firth M, editors. Buprenorphine and anaesthesiology. Roy Soc Med Int Congr Symp Ser 1984; 65: 1-148.

62.

Robbie DS A trial of sublingual buprenorphine in cancer pain. Br J Clin Pharmacol 1979; 7: 315S-17S.

63.

Adriaensen H. , Mattelaere B. , Vanmeenen H. A long-term open assessment of sublingual buprenorphine in patients suffering from chronic pain. Pain 1981: S38.

64.

Ventafridda V. , De Conno F. , Guarise G. , Tamburini M. , Savio G. Chronic analgesic study on buprenorphine action in cancer pain. Comparison with pentazocine . Arzneim-Forsch/Drug Res 1983; 33: 587-90.

65.

Dini D. , Fassio T. , Gottlieb A. , Gini M. Studio controllato sull'effeto analgesico e sulla tollerabilita della buprenorfina, in pazienti affetti da neoplasia. Min Med 1986; 77: 93-104.

66.

Enig B. Sublingual buprenorphine in the treatment of pain due to cancer. Transition to . buprenorphine from other opiates. Ugeskr Laeger 1983; 145: 3236-40.

67.

Zenz M. , Piepenbrock S. , Tryba M. et al. Glocke M. , Everlien M. , Klauke W. Kontrollierte Studie mit Buprenorphin. Dtsch med Wschr 1985; 110: 448-53.

68.

Cowan A. , Doxey JC , Harry Ejr. The animal pharmacology of buprenorphine, an oripavine analgesic agent . Br J Pharmacol 1977; 60: 547-54.

69.

Jasinski DR , Pevnick JS , Griffith JD Human pharmacology and abuse potential of the analgesic buprenorphine. Arch Gen Psychiat 1978; 35: 501-16.

70.

Robertson JR , Bucknall Abv.

Buprenorphine: dangerous drug or overlooked therapy?

Br Med J 1986; 292: 1465.

71.

Goode PG , White AC Some properties of WY 22811, a new analgesic compound. Br J Pharmacol 1971; 43: 462P-463P.

72.

Anonymous. Meptazinol. Lancet 1983; ii: 384-5.

73.

Hedges A. , Turner P. The use of intramuscular meptazinol in the relief of postoperative pain after abdominal hysterectomy - a review. Postgrad Med J 1983; 59(Suppl 1): 32-4.

74.

Bill DJ , Hartley JE , Stevens RJ , Thompson AM Antinociceptive activity of meptazinol depends on both opiate and cholinergic receptors. Br J Pharmacol 1982 ; 79: 191-99.

75.

Blurton PA , Fox J. , Wood MD , Wyllie MG Interaction of meptazinol with multiple opiate receptors. Br J Pharmacol 1982; 77: 508P.

76.

Staquet M. A double-blind comparison of meptazinol with pentazocine and placebo in cancer pain. J Clin Pharmacol 1978; 18: 76-79.

77.

Anunymous. Meptid Data Sheet . Taplow: Wyeth Laboratories, 1984.

78.

Martin WR Naloxone. Ann Intern Med 1976; 85: 765-8.

79.

Anonymous. Naloxone-opiate antagonist. Drug Ther Bull 1981; 19: 83-84.

80.

De Maria A. , Hefernan JJ , Gruidlinger GA , et al. Naloxone versus placebo in treatment of septic shock. Lancet 1985; i: 1363.

81.

Pickar D. Naloxone in schizophrenia. Lancet 1983; i: 819.

82.

Handal KA , Schanken JL , Salamone FR Naloxone. Ann Emerg Med 1983 ; 12: 438-45.

83.

Hanks GW , Hoskin PJ Pain Control in Advanced Cancer: Pharmacological Methods. J Roy Coll Physicians 1986; 20: 276-81.

84.

Joint Formulary Committee. Morphine salts. In: British National Formulary , No. 11. London: British Medical Association, 1986: 169.

85.

Bardgett D. , Howard C. , Murray GR , Calvey TN , Williams NE Plasma concentration and bioavailability of a buccal preparation of morphine sulphate. Br J Clin Pharmacol 1984; 17: 198-9P.

86.

Gruerek DE , Cowan A. , Woods JH Independent central and peripheral mediation of morphine-induced inhibition of gastrointestinal transit in rats. J Pharmacol Exp Ther 1986; 236: 8-13.

87.

Shimomura K. , Kannata O. , Ueki S. et al. Analgesic effect of morphine glucuronides. 1 Tohoku J Exp Med 1971; 105: 45-52.

88.

Sasajima M.

Analgesic effect of morphine-3-glucuronide. Keio

Med J 1970; 47: 421-6.

89.

Osborne RJ , Joel SP , Slevin ML Morphine intoxication in renal failure: the role of morphine-6-glucuronide . Br Med J 1986; 292: 1548-9.

90.

Aherne GW , Littleton P. Morphine-6-glucuronide, an important factor in interpreting morphine radioimmunoassays . Lancet 1985; ii: 210-11.

91.

Svensson JO , Rane A. , Sawe J. , Sjoquist F. Determination of morphine, morphine-3-glucuronide and (tentatively) morphine-6-glucuronide in plasma and urine using ion-pair high-performance liquid chromatography. J Chromatography 1982; 230: 427-32.

92.

Brunk SF , Delle M. Morphine metabolism in man. Clin Pharmacol Ther 1974; 16: 51-57.

93.

Omar OA , Johnstone A. , Turner P. (1986). (In preparation).

94.

Hanning CD , Smith G. , McNeill M. , Graham NB Rectal administration of morphine from a sustained release hydrogel suppository . Br JAnaesth 1985; 236p-7p.

95.

Dahlstrom BE , Paalzow LK Pharmacokinetic interpretation of the enterohepatic recirculation and first pass elimination of morphine in the rat. J Pharmacokin Biopharm 1978; 6: 505-19.

96.

Stanski DR , Greenblatt DJ , Lappas DG , Kochweser J. , Lowenstein E. Kinetics of high dose intravenous morphine in cardiac surgery patients . Clin Pharmacol Ther 1976; 19: 752-6.

97.

Dahlstrom BE , Paalzow LK , Segre G. , Agress AJ Relation between morphine pharmacokinetics and analgesia. J Pharmacokinet Biopharm 1978 ; 6: 41-53.

98.

Stanski DR , Greenblatt DJ , Lowenstein E. Kinetics of intravenous and intramuscular morphine. Clin Pharmacol Ther 1978; 24: 52-9.

99.

Aitkenhead AR , Vater M. , Achola K. , Cooper MS , Smith G. Pharmacokinetics of single dose IV morphine in normal volunteers and patients with end-stage renal failure. Br J Anaesth 1984; 56: 813-19.

100.

Murphy MD , Hug CC Pharmacokinetics of intravenous morphine in patients anaesthetized with enflurane-nitrous oxide. Anaesthesiology 1981; 54: 187-92.

101.

Cravey RH , Reed D. Distribution of morphine in man following chronic intravenous administration . J Analyt Toxicol 1977; 1: 166-7.

102.

Felby S. , Christensen H. , Lund A. Morphine concentrations in blood and organs in cases of fatal poisoning. Forensic Sci 1974; 3: 77-81.

103.

Olsen GD Morphine binding to human plasma proteins. Clin Pharmacol Ther 1975; 17: 31-35.

104.

Boerner U. , Abbott S. , Roe RL The metabolism of morphine and heroin in man . Drug Metab Rev 1975; 4(1): 39-73.

105.

Sawe J. , Dahlstrom B. , Rane A. Morphine kinetics in cancer patients. Clin Pharmacol Ther 1981; 30: 629-35 .

106.

Sawe J. , Svensson JO , Rane A. Morphine metabolism in cancer patients on increasing oral doses - no evidence for autoinduction or dose dependence. Br J Clin Pharmacol 1983; 16: 85-93.

107.

Dahlstrom BE , Jonsson J. , Paalzow LK Metabolism of morphine in the perfused rat liver. Acta Pharmacol Toxicol 1976; 39: 46-52.

108.

Dahlstrom BE , Paalzow LK Pharmacokinetic interpretation of the enterohepatic recirculation and first pass elimination of morphine in the rat. J Pharmacokinet Biopharm 1978 ; 6: 505-79.

109.

Sawe J. , Pacifici GM , Kager L. , Van Bahr C. , Rane A. Glucuronidation of morphine in human liver and interaction with oxazepam. Acta Anaesth Scand 1982; 74: 47-51.

110.

Sawe J. , Kager L. , Svensson JO , Rane A.

Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation. Br

J Clin Pharmacol 1985; 19: 495-501.

111.

Patwardhan RV , Johnson RF , Hoyumpa A. et al. Normal metabolism of morphine in cirrhosis . Gastroenterology 1981; 81: 1006-11.

112.

Hasselstrom J. , Eriksson LS , Persson A. , Rane A. , Svensson J. , Sawe J. Morphine metabolism in patients with liver cirrhosis. Proceedings 3rd World Conference on Clinical Pharmacology and Therapeutics 1986; Abstracts: 101.

113.

Schali C. , Roch-Ramel F. Transport and metabolism of 3[H] morphine in isolated, non-perfused proximal tubular segments of the rabbit kidney. J Pharmacol Exp Ther 1982; 223: 811-15.

114.

McQuay HJ , Moore RA , Bullingham Res , Sear JW , Symonds HW Extrahepatic morphine metabolism. Roy Soc Med Int Congr Symp Ser 1983; 64: 111-22.

115.

Neuman PB , Henriksen H. , Grosman N. , Christensen CB Plasma morphine concentrations during chronic oral administration in patients with cancer pain. Pain 1982; 13: 247-52.

116.

Moore A. , Sear J. , Baldwin D. et al. Morphine kinetics during and after renal transplantation. Clin Pharmacol Ther 1984; 35: 641-5.

117.

McQuay HJ , Moore RA , Bullingham Res et al. High systemic relative bioavailability of oral morphine in both solution and sustained release formulation. Roy Soc Med Int Cong Symp Ser 1983; 64: 149-54.

118.

Regnard Cfb , Twycross RG Metabolism of narcotics. Br Med J 1984; 288: 860.

119.

Hanks GW , Aherne GW

Morphine metabolism: does the renal hypothesis hold water?

Lancet 1975; i: 221-22.

120.

Sawe J. , Svensson JO , Odar-Cederlof I. Kinetics of morphine in patients with renal failure. Lancet 1985; i: 211.

121.

Woolner DF , Winter D. , Frendin TJ et al. Renal failure does not impair the metabolism of morphine. Br J Clin Pharmacol 1986; 22: 55-59.

122.

Berkowitz BA The relationship of pharmacokinetics to pharmacological activity: Morphine, Methadone and Naloxone. Clin Pharmacokinet 1976; 1: 219-30.

123.

Garrett R. , Jackson AJ Pharmacokinetics of morphine and its surrogates III: Morphine and morphine-3-mono-glucuronide pharmacokinetics in the dog as a function of dose. J Pharm Sciences 1979 ; 68: 753-71.

124.

Walsh CT , Levine RR Studies of the enterohepatic circulation of morphine in the rat. J Pharmacol Exp Ther 1975; 195: 303-10.

125.

Hanks GW , Rose NM , Aherne GW et al. Controlled release morphine tablets: a double blind trial in dental surgery patients. Br J Anaesth 1980 ; 53: 1259-63.

126.

Leslie ST , Rhodes A. , Black FM Controlled release morphine sulphate tablets - a study in normal volunteers . Br J Clin Pharmacol 1980; 9: 531-4.

127.

Hanks GW , Twycross RG Pain, the physiological antagonist of opioid analgesics. Lancet 1984; i: 1477-8.

128.

Hanks GW Antiemetics for terminal cancer patients. Lancet 1982; i: 1410.

129.

Walsh TD , Baxter R. , Bowman K. , Leben B. High dose morphine and respiratory function in chronic cancer pain . Pain 1981; Suppl. 1: 539.

130.

Jones VA , Hanks GW New portable infusion pump for prolonged subcutaneous administration of opioid analgesics in patients with advanced cancer. Br Med J 1986; 292: 1496.

131.

Waldmann CS , Eason JR , Rambohul E. , Hanson GC Serum morphine levels: a comparison between continuous subcutaneous infusion and continuous intravenous infusion in postoperative patients. Anaesthesia 1984; 39: 768-71.

132.

Graves DA , Foster TS , Batenhorst RL , Bennett RL , Baumann TJ Patient controlled analgesia. Ann Intern Med 1983; 99: 360-66.

133.

Leading Article . Patient-controlled analgesia. Lancet 1980; i: 289.

134.

Hanks GW , Thomas EA Intravenous opioids in chronic cancer pain. Br Med J 1985; 291: 1124-5.

135.

Houde RW , Wallenstein SL , Beaver WT Clinical measurement of pain. In: de Stevens G editor. Analgetics. New York. Academic Press.

136.

Twycross RG The relief of pain in far advanced cancer. Regional Anaesth 1980; 5: 2-11

137.

Kaiko RF Controversy in the management of chronic cancer pain: therapeutic equivalents of IM and PO morphine. Journal of Pain and Symptom Management 1985; 1: 42-45.

138.

Yaksh TL , Rudy TA Analgesia mediated by direct spinal action of narcotics. Science 1976; 192: 1357-8.

139.

Paterson Gmc , McQuay HJ , Bullingham Res , Moore RA Intradural morphine and diamorphine dose response studies. Anaesthesia 1984; 39: 113-17.

140.

Moore A. , Bullingham R. , McQuay H. et al. Spinal fluid kinetics of morphine and heroin. Clin Pharmacol Ther 1984; 35: 40-45.

141.

Watson Pjq , Moore RA , McQuay HJ Plasma morphine concentrations and analgesic effects of lumbar extradural morphine and heroin. Anaesth Analgesia 1984; 63: 629-34.

142.

Leading Article . Spinal opiates revisited. Lancet 1986; i: 655-6.

143.

Davies GK , Tolhurst-Cleaver CL , James TL Respiratory depression after intrathecal narcotics. Anaesthesia 1980; 35: 1080-3.

144.

Justin DM , Reynolds F.

Intraspinal opiates and itching: a new reflex?

Br MedJ 1982; 284: 1401.

145.

Isbell H. Pharmacological factors in drug dependence. Adv Exp Med Biol 1972; 20: 35-42.

146.

Jaffe JH Drug addiction and drug abuse. In: Gilman AF, Goodman LS, Rall TW, Murad F. The Pharmacological Basis of Therapeutics, seventh edition. New York: Macmillan, 1980: 532-81.

147.

Walsh TD Comon misunderstandings about the use of morphine for chronic pain in advanced cancer. CA -A Journal for Clinicians 1985 ; 35: 164-9 .

148.

Hanks GW , Twycross RG , Lloyd J. Unexpected complication of successful nerve block. Anaesthesia 1981; 36: 37-39.

149.

Sawe J. , Svensson J-O. , Rawe A. Morphine metabolism in cancer patients on increasing oral doses - no evidence for autoinduction or dose-dependence. Br J Clin Pharmacol 1983; 16: 85-93.

150.

Porter J. , Jick H. Addiction rare in patients treated with narcotics. N Eng J Med 1980; 302: 123.

151.

Martindale: The Extra Pharmacopoeia, 28th edition. London: The Pharmaceutical Press: 1008.

152.

Jones V. , Murphy A. , Hanks GW Solubility of diamorphine. Pharmaceut J 1985 ; 235: 426.

153.

Beaumont IM Stability study of aqueous solutions of diamorphine and morphine using HPLC. Pharmaceut J 1982 ; 229: 39-41.

154.

Cooper H. , Melita AC , Calvert RT Stability of diamorphine in chloroform water mixture. Pharmaceut J 1981; 226: 682-3.

155.

Jones V. , Hoskin PJ , Omar OA et al. Stability of aqueous solutions of diamorphine for subcutaneous infusion (in preparation).

156.

Inturissi CE , Schultz M. , Shir S. et al. Evidence from opiate binding studies that heroin acts through its metabolites. Life Sci (Suppl. 1) 1983; 33: 773-6.

157.

Inturissi CE , Max MB , Foley KM et al. The pharmacokinetics of heroin in patients with chronic pain . N Engl J Med 1984; 310: 1213-17.

158.

Umans JG , Chin Tsk , Lipman RA et al. Determination of heroin and its metabolites by high performance liquid chromatography. J Chromatography 1982 ; 233: 213-25.

159.

Inturissi C. , Foley K. , Max M. et al. Disposition and effects of heroin in pain patients. Clin J Pain 1985; 1: 111-15.

160.

Way EL , Young JM , Kemp JW Metabolism of heroin and its pharmacologic implications. Bulletin on Narcotics 1965; XVII (i): 25-33.

161.

Inturissi CE Pharmacokinetics of oral intravenous and continuous infusions of heroin. Adv Pain Res Ther 1986 ; 8: 117-27.

162.

Elliott HW , Parker KD , Wright JA , Nomef N. Actions and metabolism of heroin administered by continuous infusion to man. Clin Pharmacol Ther 1971; 12: 806.

163.

Kaiko RF , Wallenstein SL , Rogers AG , Grabinsky PY , Houde RW Analgesic and mood effects of heroin and morphine in cancer patients with postoperative pain. N Eng J Med 1981; 304: 1501-5.

164.

Bolsen B. US Trials show heroin not superior to morphine. J Am Med Assoc 1982; 247: 2471.

165.

Twycross RG , Fry DE , Wills PD The alimentary absorption of diamorphine and morphine in man as indicated by urinary excretion studies. Br J Clin Pharmacol 1972; 1: 491-4.

166.

Levine MN , Sachett DL , Bush H. Heroin vs morphine for cancer pain. Arch Intern Med 1986; 146: 353-6.

167.

Anonymous. Phenazocine. Drug Ther Bull 1979; 18: 70.

168.

Szeto H. , Inturissi CE , Houde R. et al. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure or cancer. Ann Intern Med 1977; 86: 738-41.

169.

Twycross RG Relief of pain: strong narcotic analgesics. In: Saunders CM editor. The management of terminal malignant disease, second edition. London: Edward Arnold, 1984: 75-81.